| Safety of Intranodal ECI-006 in Melanoma Patients (NCT03394937) | eTheRNA immunotherapies | 2017-06-27 |
| SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma (NCT02986867) | University of Texas Southwestern Medical Center | 2017-06-13 |
| Feedback in the Consultation - a Dialogue-based Tool in Personalised Care Planning Using Systematic Patient Involvement (NCT03163433) | University of Aarhus | 2017-06-12 |
| A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (NCT03052205) | Idera Pharmaceuticals, Inc. | 2017-06-09 |
| LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma (NCT03101254) | Dana-Farber Cancer Institute | 2017-06-06 |
| Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases (NCT02978404) | Centre hospitalier de l'Université de Montréal (CHUM) | 2017-06-02 |
| APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (NCT02706353) | M.D. Anderson Cancer Center | 2017-06-02 |
| MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients (NCT02962947) | Azienda Sanitaria di Firenze | 2017-06-01 |
| Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (NCT03114319) | Novartis Pharmaceuticals | 2017-05-26 |
| PD-L1 PET Imaging in Melanoma Patients (NCT03520634) | University Medical Center Groningen | 2017-05-22 |
| Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma (NCT03159117) | Memorial Sloan Kettering Cancer Center | 2017-05-16 |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor (NCT03132922) | USWM CT, LLC | 2017-05-15 |
| Immunotherapy Study of Evofosfamide in Combination With Ipilimumab (NCT03098160) | Threshold Pharmaceuticals | 2017-05-10 |
| Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma (NCT02447939) | GlaxoSmithKline | 2017-05-01 |
| Dendritic Cell Vaccination in Patients With Advanced Melanoma (NCT03092453) | University of Pennsylvania | 2017-05-01 |
| Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma (NCT02968680) | University of Southern California | 2017-04-26 |
| Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer (NCT05740501) | Mayo Clinic | 2017-04-26 |
| Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker (NCT03089606) | UNC Lineberger Comprehensive Cancer Center | 2017-04-19 |
| An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (NCT03068455) | Bristol-Myers Squibb | 2017-04-11 |
| An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) (NCT03002376) | Regeneron Pharmaceuticals | 2017-04-10 |
| Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers (NCT02830724) | National Cancer Institute (NCI) | 2017-04-06 |
| Post-ATU Study of Nivolumab (NCT03325257) | Nantes University Hospital | 2017-03-09 |
| Nivolumab Plus Radiotherapy in Advanced Melanoma (NCT02799901) | Centre Hospitalier Universitaire de Nice | 2017-03-03 |
| A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan (NCT03165422) | Bristol-Myers Squibb | 2017-03-01 |
| Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread (NCT03165409) | Bristol-Myers Squibb | 2017-02-27 |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (NCT02974725) | Novartis Pharmaceuticals | 2017-02-24 |
| A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (NCT02967692) | Novartis Pharmaceuticals | 2017-02-17 |
| Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma (NCT03313323) | Amsterdam UMC, location VUmc | 2017-02-16 |
| BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma (NCT02872259) | Haukeland University Hospital | 2017-02-13 |
| A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma (NCT02975700) | Daiichi Sankyo Co., Ltd. | 2017-01-31 |
| A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma (NCT02908672) | Hoffmann-La Roche | 2017-01-13 |
| Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component) (NCT03253666) | Harvard School of Public Health (HSPH) | 2017-01-01 |
| Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma (NCT03026517) | Memorial Sloan Kettering Cancer Center | 2017-01-01 |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers (NCT02643303) | Ludwig Institute for Cancer Research | 2016-12-28 |
| Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma (NCT03504696) | Bristol-Myers Squibb | 2016-12-20 |
| A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (NCT02983045) | Nektar Therapeutics | 2016-12-19 |
| Long Term Quality of Life in Melanoma Patients in Netherlands (NCT03450876) | Bristol-Myers Squibb | 2016-12-15 |
| [18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis (NCT02700763) | University Medical Center Groningen | 2016-12-06 |
| Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy (NCT02990611) | Bristol-Myers Squibb | 2016-12-06 |
| High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma (NCT03007823) | Fuda Cancer Hospital, Guangzhou | 2016-12-01 |
| Adoptive Therapy Using Antigen-Specific CD4 T-Cells (NCT02210104) | M.D. Anderson Cancer Center | 2016-12-01 |
| Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma (NCT02970981) | NYU Langone Health | 2016-11-29 |
| Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors (NCT02988817) | Genmab | 2016-11-23 |
| Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma Patients (NCT02949154) | University Medical Center Groningen | 2016-11-01 |
| A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma (NCT02905266) | Bristol-Myers Squibb | 2016-10-27 |
| A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) (NCT03139513) | Hoffmann-La Roche | 2016-10-27 |
| Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States (NCT03199846) | Bristol-Myers Squibb | 2016-10-25 |
| Pembrolizumab-PET Imaging (NCT02760225) | University Medical Center Groningen | 2016-10-24 |
| IL2 Imaging in Metastatic Melanoma (NCT02922283) | University Medical Center Groningen | 2016-10-20 |
| Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma (NCT02659540) | Ludwig Institute for Cancer Research | 2016-10-13 |
| 18F-FLT PET Imaging in Patients With Advanced Melanoma (NCT02891616) | Washington University School of Medicine | 2016-10-10 |
| Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab (NCT02515227) | Craig L Slingluff, Jr | 2016-10-06 |
| Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma (NCT02482532) | Gary Doolittle | 2016-10-06 |
| Study of ASN003 in Subjects With Advanced Solid Tumors (NCT02961283) | Asana BioSciences | 2016-10-01 |
| Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo (NCT02902822) | Centro Studi Gised | 2016-10-01 |
| Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma (NCT02983006) | NYU Langone Health | 2016-10-01 |
| Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma (NCT03095079) | Peking University Cancer Hospital & Institute | 2016-10-01 |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer (NCT02897765) | BioNTech US Inc. | 2016-10-01 |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers (NCT02989064) | Adaptimmune | 2016-10-01 |
| Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone (NCT02736123) | University of Pittsburgh | 2016-10-01 |
| Yervoy Pregnancy Surveillance Study (NCT02854488) | Bristol-Myers Squibb | 2016-09-30 |
| X4P-001 and Pembrolizumab in Patients With Advanced Melanoma (NCT02823405) | X4 Pharmaceuticals | 2016-09-15 |
| Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (NCT02869217) | University Health Network, Toronto | 2016-09-01 |
| Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab (NCT02909348) | Royal Free Hospital NHS Foundation Trust | 2016-09-01 |
| A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma. (NCT02821182) | University Hospital, Ghent | 2016-09-01 |
| Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides (NCT02890368) | Pfizer | 2016-09-01 |
| A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study (NCT02796352) | Ahmad Tarhini | 2016-09-01 |
| Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer (NCT02718066) | HUYABIO International, LLC. | 2016-08-18 |
| An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo (NCT02763761) | Bristol-Myers Squibb | 2016-08-16 |
| Trial of Pembrolizumab and Radiotherapy in Melanoma (NCT02562625) | Royal Marsden NHS Foundation Trust | 2016-08-11 |
| Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (NCT02906943) | University Health Network, Toronto | 2016-08-01 |
| Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases (NCT02621515) | University Medical Center Groningen | 2016-08-01 |
| Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions (NCT02862145) | Mirna Therapeutics, Inc. | 2016-08-01 |
| Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) (NCT02771626) | Calithera Biosciences, Inc | 2016-08-01 |
| Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice (NCT02847728) | Bristol-Myers Squibb | 2016-07-28 |
| Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma (NCT02818023) | Yana Najjar | 2016-07-13 |
| Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) (NCT02821000) | Merck Sharp & Dohme LLC | 2016-07-08 |
| Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy (NCT02839694) | National Cancer Institute (NCI) | 2016-07-07 |
| Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma (NCT02656706) | Brown University | 2016-07-01 |
| A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) (NCT02576665) | Tocagen Inc. | 2016-07-01 |
| M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma (NCT00477906) | AVAX Technologies | 2016-07-01 |
| Family Lifestyle Actions and Risk Education Study (NCT02846714) | University of Utah | 2016-07-01 |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (NCT02807844) | Novartis Pharmaceuticals | 2016-06-29 |
| Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma (NCT02743819) | University of Chicago | 2016-06-28 |
| Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma (NCT02723006) | Millennium Pharmaceuticals, Inc. | 2016-06-22 |
| A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) (NCT02752074) | Incyte Corporation | 2016-06-21 |
| Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy (NCT02731729) | Parker Institute for Cancer Immunotherapy | 2016-06-21 |
| A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors (NCT02819843) | Memorial Sloan Kettering Cancer Center | 2016-06-21 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (NCT02432963) | City of Hope Medical Center | 2016-06-14 |
| Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers (NCT01528774) | Wolfram Samlowski | 2016-06-01 |
| HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma (NCT02836548) | The Netherlands Cancer Institute | 2016-06-01 |
| Molecular Analysis of Childhood and Adolescent Melanocytic Lesions (NCT02775643) | St. Jude Children's Research Hospital | 2016-05-31 |
| GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients (NCT02575404) | Providence Health & Services | 2016-05-16 |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (NCT02668770) | M.D. Anderson Cancer Center | 2016-05-11 |
| Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners (NCT02854657) | Northwestern University | 2016-05-01 |
| Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) (NCT02681549) | Yale University | 2016-05-01 |
| A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. (NCT02711345) | Novartis Pharmaceuticals | 2016-04-15 |
| An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (NCT02658890) | Bristol-Myers Squibb | 2016-04-14 |
| Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy (NCT02680184) | Regeneron Pharmaceuticals | 2016-04-12 |
| A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma (NCT02714218) | Bristol-Myers Squibb | 2016-04-04 |